Inventor · disambiguated record
Steven T. Miller
Also filed as: MILLER STEVEN · MILLER STEVEN T
29 granted patents·13 pending applications·183 citations·filing 1993–2020
96Inventor score
Top patents by PatentIndex Score
42 records- 0189US5696166ACompositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disordersFiled 1995·Granted Dec 9, 1997·93 cites·7 claims
- 0286US8222227B2RNAi-mediated inhibition of histamine receptor H1-related conditionsYANNI JOHN M·Filed 2011·Granted Jul 17, 2012·6 cites·13 claims
- 0385US8017592B2RNAi-mediated inhibition of histamine receptor H1-related conditionsALCON RES LTD·Filed 2007·Granted Sep 13, 2011·5 cites·13 claims
- 0484US7732421B2RNAI-mediated inhibition of tumor necrosis factor α-related conditionsALCON RES LTD·Filed 2007·Granted Jun 8, 2010·4 cites·12 claims
- 0583US7713975B13,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseasesALCON INC·Filed 2006·Granted May 11, 2010·7 cites·6 claims
- 0682US8048863B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsALCON RES LTD·Filed 2007·Granted Nov 1, 2011·3 cites·36 claims
- 0780US9453220B2RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disordersARROWHEAD RES CORP·Filed 2014·Granted Sep 27, 2016·2 cites·8 claims
- 0879US9206428B2RNAi-mediated inhibition of histamine receptor H1-related conditionsARROWHEAD RES CORP·Filed 2013·Granted Dec 8, 2015·2 cites·17 claims
- 0978US8618278B2RNAi-mediated inhibition of histamine receptor H1-related conditionsYANNI JOHN M·Filed 2012·Granted Dec 31, 2013·2 cites·4 claims
- 1077US8673873B1RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disordersYANNI JOHN M·Filed 2009·Granted Mar 18, 2014·1 cites·6 claims
- 1176US7799778B15-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseasesALCON INC·Filed 2006·Granted Sep 21, 2010·2 cites·6 claims
- 1274US6372802B2Aniline disulfide derivatives for treating allergic diseasesALCON UNIVERSAL LTD·Filed 2001·Granted Apr 16, 2002·6 cites·15 claims
- 1370US2008096852A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeALCON INC·Filed 2007·Application pending·0 cites
- 1467US2019032061A1RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related ConditionsARROWHEAD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 1566US9447419B2RNAi-mediated inhibition of tumor necrosis factor α-related conditionsARROWHEAD RES CORP·Filed 2014·Granted Sep 20, 2016·0 cites·12 claims
- 1666US6452052B1Aniline disulfide derivatives for treating allergic diseasesALCON UNIVERSAL LTD·Filed 2002·Granted Sep 17, 2002·2 cites·3 claims
- 1765US6225327B1Compounds which inhibit human conjunctival mast cell degranulation for treating ocular allergic-type complicationsALCON LAB INC·Filed 1997·Granted May 1, 2001·28 cites·3 claims
- 1864US9765340B2RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disordersARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Sep 19, 2017·0 cites·21 claims
- 1964US6506802B2Disulfide derivatives useful for treating allergic diseasesALCON UNIVERSAL LTD·Filed 2002·Granted Jan 14, 2003·1 cites·8 claims
- 2064US6500864B1Disulfide derivatives useful for treating allergic diseasesALCON UNIVERSAL LTD·Filed 2002·Granted Dec 31, 2002·1 cites·7 claims
- 2164US6492552B2Disulfide derivatives useful for treating allergic diseasesALCON UNIVERSAL LTD·Filed 2001·Granted Dec 10, 2002·1 cites·1 claims
- 2263US9371529B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsARROWHEAD RES CORP·Filed 2014·Granted Jun 21, 2016·0 cites·13 claims
- 2363US2006058277A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeYANNI JOHN M·Filed 2005·Application pending·0 cites
- 2463US2004132704A1Use of oculosurface selective glucocorticoid in the treatment of dry eyeFiled 2003·Application pending·0 cites
- 2562US6492418B2Compositions containing a benzamide disulfide derivative for treating allergic diseasesALCON UNIVERSAL LTD·Filed 2001·Granted Dec 10, 2002·1 cites·7 claims
- 2662US2013338213A1RNAi-MEDIATED INHIBITION OF TUMOR NECROSIS FACTOR ALPHA-RELATED CONDITIONSALCON RES LTD·Filed 2013·Application pending·0 cites
- 2761US2016369283A1RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related ConditionsARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2860US2006217325A1Treatment of dry eye restoring 15-lipoxygenase activity to ocular surface cellsALCON INC·Filed 2003·Application pending·0 cites
- 2960US2004248794A1Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cellsFiled 2003·Application pending·0 cites
- 3060US2008139531A1Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repairALCON MFG LTD·Filed 2007·Application pending·0 cites
- 3158US9745585B2RNAi-mediated inhibition of histamine receptor H1-related conditionsARROWHEAD RES CORP·Filed 2015·Granted Aug 29, 2017·0 cites·16 claims
- 3258US8541389B2RNAi-mediated inhibition of tumor necrosis factor α-related conditionsYANNI JOHN M·Filed 2011·Granted Sep 24, 2013·0 cites·6 claims
- 3356US8865671B2RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditionsYANNI JOHN M·Filed 2011·Granted Oct 21, 2014·0 cites·21 claims
- 3455US12503688B2Engineered transaminase polypeptidesCODEXIS INC·Filed 2020·Granted Dec 23, 2025·0 cites·27 claims
- 3555US2016257963A1RNAi-MEDIATED INHIBITION OF SPLEEN TYROSINE KINASE-RELATED INFLAMMATORY CONDITIONSARROWHEAD PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3652US5360720AMethod of preparing human conjunctival mast cells for mast cell stabilization assaysALCON LAB INC·Filed 1993·Granted Nov 1, 1994·12 cites·10 claims
- 3750US2009182035A1Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitisALCON RES LTD·Filed 2009·Application pending·0 cites
- 3848US2008254029A1Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic ConjunctivitisALCON RES LTD·Filed 2008·Application pending·0 cites
- 3947US7906512B23,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseasesALCON INC·Filed 2010·Granted Mar 15, 2011·0 cites·8 claims
- 4041US2002077358A1Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgeryALCON UNIVERSAL LTD·Filed 2001·Application pending·0 cites
- 4139US6225332B1Compositions containing histamine H2 agonists and methods of use in treating allergy and inflammationALCON LAB INC·Filed 1998·Granted May 1, 2001·4 cites·5 claims
- 4231US6274160B1Methods of use of histamine H2 agonists in treating dry eyeALCON LAB INC·Filed 1998·Granted Aug 14, 2001·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Steven T. Miller files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →